EMEA-002499-PIP03-24 - paediatric investigation plan
tafasitamab
PIPHuman
Danish is available via eTranslation, the European Commission's machine translation service.
Translate to Danish | Important information about machine translation
Key facts
- Invented name
- Minjuvi
- Active substance
- tafasitamab
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0344/2024
- PIP number
- EMEA-002499-PIP03-24
- Pharmaceutical form(s)
- Powder for concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of mature B-cell neoplasms excluding diffuse large B-cell lymphoma
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Incyte Biosciences Distribution B.V.
E-mail: RA@incyte.com
Tel. +1 3024252734- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Nej